Natco Pharma.
Indian pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 13
What's happening
Earlier this month
One to three months ago
-
Natco Pharma's board of directors approved a major capital-raising plan on September 9, 2026.Some support2 reports
-
Natco Pharma produced a generic version of a Bayer drug, while Akshaya expanded its network in Kerala.Some support1 report
-
Natco Pharma and Bonus were identified as dividend payers in the market.Some support1 report
-
Natco Pharma and Novartis are challenging patent exclusivity of the drug ribociclib in the Delhi High Court.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Natco Pharma this week
News at the entities that move Natco Pharma most-
Novartis OperationalSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Natco Pharma
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Natco Pharma
-
Delhi High Court OperationalDelhi High Court set aside a CIC order concerning flight records involving the Indian Air Force.Moves Natco Pharma
-
AstraZeneca OperationalAstraZeneca is relocating its registered office from Karnataka to Bengaluru, citing proximity to policy and financial ecosystems.Moves Natco Pharma
-
BAYER OperationalBayer is conducting INERA trials spanning 100 acres in India and plans to distribute the product.Moves Natco Pharma
-
India Shared contextReport tracks the mobility credit market in India, noting that NBFCs are leading vehicle financing.Moves Natco Pharma
Connections
The 8 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Operational
The two companies are engaged in direct market competition regarding the patent exclusivity of the drug ribociclib.
-
FDA Structural
The FDA, as the regulatory body, granted tentative approval for Olaparib tablets, directly impacting Natco Pharma's product lifecycle.
-
AstraZeneca Operational
Natco manufactures a bioequivalent version of Olaparib to AstraZeneca's Lynparza, establishing direct market competition.
-
BAYER Operational
Natco Pharma produces generic versions of Bayer's drugs, establishing a direct market competition based on the original product.
-
Delhi High Court Operational
Natco Pharma is actively petitioning the Delhi High Court regarding patent office decisions.
-
Bonus Mentioned together
Both entities are noted as dividend payers in the market.
-
India Shared context
Natco Pharma operates as an Indian company within the national and global market context.
-
RSI Mentioned together
No direct relationship between the two entities is established in the provided evidence.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
4 events- India and Natco Pharma are investing in the U.S. biotech company eGenesis.
- Natco Pharma produced a generic version of a Bayer drug, while Akshaya expanded its network in Kerala.
- Natco Pharma and Bonus were identified as dividend payers in the market.
- Natco Pharma and Novartis are challenging patent exclusivity of the drug ribociclib in the Delhi High Court.